{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-3967"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-3967","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"SELECTIVE SMALL MOLECULE TARGETING OF MCL-1 IN MULTIPLE MYELOMA","abstract":"Multiple Myeloma (MM) is a deadly blood malignancy, characterized by the uncontrolled proliferation of aberrantly differentiated plasma cells. MM is challenging to diagnose and treat, accounting for approximately 12% of hematologic malignancies. The overexpression of anti-apoptotic group of Bcl-2 family proteins, particularly Myeloid cell leukemia 1 (Mcl-1), play a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis. Thus, inhibition of the Mcl-1 protein is an attractive therapeutic strategy against myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. In this project, we investigated the effect of the novel Mcl-1 inhibiting agent KS18 on MM cells. We demonstrated the molecules in vitro efficacy as well superior potency towards MM. However, Mcl-1 inhibition by KS18 was associated with a significant reduction of MM cell viability. Moreover, we observed that KS18 was able to induce apoptosis in MM cells in a caspase-dependent manner. Our results propose that targeting Mcl-1 by KS18 may represent a new viable strategy for MM treatment. Furthermore, the present study uncovers the mechanism of action of KS18 and provides the foundation for in vivo assessment of this novel molecule.","abstract_html":"Multiple Myeloma (MM) is a deadly blood malignancy, characterized by the uncontrolled proliferation of aberrantly differentiated plasma cells. MM is challenging to diagnose and treat, accounting for approximately 12% of hematologic malignancies. The overexpression of anti-apoptotic group of Bcl-2 family proteins, particularly Myeloid cell leukemia 1 (Mcl-1), play a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis. Thus, inhibition of the Mcl-1 protein is an attractive therapeutic strategy against myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. In this project, we investigated the effect of the novel Mcl-1 inhibiting agent KS18 on MM cells. We demonstrated the molecules in vitro efficacy as well superior potency towards MM. However, Mcl-1 inhibition by KS18 was associated with a significant reduction of MM cell viability. Moreover, we observed that KS18 was able to induce apoptosis in MM cells in a caspase-dependent manner. Our results propose that targeting Mcl-1 by KS18 may represent a new viable strategy for MM treatment. Furthermore, the present study uncovers the mechanism of action of KS18 and provides the foundation for in vivo assessment of this novel molecule.","abstract_has_math":false,"creators":["Al Odat, Omar S."],"institution":null,"degree_name":"M.S. Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:24Z","subjects":["Myeloid cell leukemia 1 (Mcl-1)","Mcl-1 inhibiting agent KS18","Multiple Myeloma--Treatment","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/2965","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/2965","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-3967","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Al Odat, Omar S."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-01-25T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2022-01-24T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S. Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Myeloid cell leukemia 1 (Mcl-1)","Mcl-1 inhibiting agent KS18","Multiple Myeloma--Treatment","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/2965"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Multiple Myeloma (MM) is a deadly blood malignancy, characterized by the uncontrolled proliferation of aberrantly differentiated plasma cells. MM is challenging to diagnose and treat, accounting for approximately 12% of hematologic malignancies. The overexpression of anti-apoptotic group of Bcl-2 family proteins, particularly Myeloid cell leukemia 1 (Mcl-1), play a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis. Thus, inhibition of the Mcl-1 protein is an attractive therapeutic strategy against myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. In this project, we investigated the effect of the novel Mcl-1 inhibiting agent KS18 on MM cells. We demonstrated the molecules in vitro efficacy as well superior potency towards MM. However, Mcl-1 inhibition by KS18 was associated with a significant reduction of MM cell viability. Moreover, we observed that KS18 was able to induce apoptosis in MM cells in a caspase-dependent manner. Our results propose that targeting Mcl-1 by KS18 may represent a new viable strategy for MM treatment. Furthermore, the present study uncovers the mechanism of action of KS18 and provides the foundation for in vivo assessment of this novel molecule."]},{"key":"dc:title","label":"Title","values":["SELECTIVE SMALL MOLECULE TARGETING OF MCL-1 IN MULTIPLE MYELOMA"]}]}],"canonical_facts":{"dc:contributor":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."],"dc:creator":["Al Odat, Omar S."],"dc:date.available":["2022-01-25T08:00:00Z"],"dc:date.created":["2022-01-24T08:00:00Z"],"dc:description.abstract":["Multiple Myeloma (MM) is a deadly blood malignancy, characterized by the uncontrolled proliferation of aberrantly differentiated plasma cells. MM is challenging to diagnose and treat, accounting for approximately 12% of hematologic malignancies. The overexpression of anti-apoptotic group of Bcl-2 family proteins, particularly Myeloid cell leukemia 1 (Mcl-1), play a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis. Thus, inhibition of the Mcl-1 protein is an attractive therapeutic strategy against myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. In this project, we investigated the effect of the novel Mcl-1 inhibiting agent KS18 on MM cells. We demonstrated the molecules in vitro efficacy as well superior potency towards MM. However, Mcl-1 inhibition by KS18 was associated with a significant reduction of MM cell viability. Moreover, we observed that KS18 was able to induce apoptosis in MM cells in a caspase-dependent manner. Our results propose that targeting Mcl-1 by KS18 may represent a new viable strategy for MM treatment. Furthermore, the present study uncovers the mechanism of action of KS18 and provides the foundation for in vivo assessment of this novel molecule."],"dc:identifier":["https://rdw.rowan.edu/etd/2965"],"dc:subject":["Myeloid cell leukemia 1 (Mcl-1)","Mcl-1 inhibiting agent KS18","Multiple Myeloma--Treatment","Pharmacy and Pharmaceutical Sciences"],"dc:title":["SELECTIVE SMALL MOLECULE TARGETING OF MCL-1 IN MULTIPLE MYELOMA"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S. Pharmaceutical Sciences"]},"updated_at":"2026-11-19T08:59:24Z"}